Ibex Medical Analytics Overview
Pro stress-test →Ibex Medical Analytics develops AI-based diagnostics technology designed to improve clinical decision-making and streamline pathology laboratory workflows, combining artificial intelligence, data science, image analysis, and machine-learning technologies to reveal underlying patterns and extract valuable clinical insights from digitized glass slides and electronic medical records. The company was founded with a focus on applying artificial intelligence to medicine, particularly advancing cancer care.
Strategic Profile
Pro stress-test →The company has developed the GALEN platform for treatment diagnosis and planning, plus products such as First Read and Second Read that use AI technology for cancer diagnosis based on pathological image analysis. Ibex's AI algorithms are developed from rich datasets extracted from over 10 million slides from multiple pathology institutes and are trained by teams of expert pathologists using deep learning technologies.
Competitive Landscape
Pro stress-test →Ibex's top competitors include PAIGE, Aignostics and Onc.ai. Other notable competitors in AI-powered pathology include PathAI, Proscia, Mindpeak, and Ellogon.AI. Ibex differentiates through early market entry, broad international deployment, clinical validation, and a comprehensive product portfolio spanning multiple cancer types.
Industry Context
Ibex Medical Analytics operates in AI-powered digital pathology.
Key facts
Founded: 2016 · Headquarters: Ramat Gan, Israel · Employees: 105 · Revenue: $15.8M